{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-012137","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.907374+00:00","generated_at":"2026-05-31T09:20:48.824613+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NeuroBo Q2 net loss $10.1M; cash $27.9M; DA-1726 SAD fully enrolled","bullets":["Net loss Q2 2024 $10.1M ($1.85/sh) vs $0.7M ($0.15/sh) Q2 2023; R&D expense rose to $8.1M from $2.4M.","Cash $27.9M at June 30, 2024; expects to fund operations into Q2 2025; closed $20M upfront financing with up to $50M milestone warrants.","DA-1726 SAD Part 1 fully enrolled (45 patients); top-line data expected Q3 2024; MAD Part 2 top-line Q1 2025.","DA-1241 MASH Phase 2a top-line results expected Q4 2024; pre-clinical combination data with semaglutide presented.","Signed joint research agreement for once-monthly DA-1726 formulation; out-licensed NB-01 for painful diabetic neuropathy."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-012137","json":"https://secwatch.observer/filing/0001558370-24-012137.json","markdown":"https://secwatch.observer/filing/0001558370-24-012137.md","text":"https://secwatch.observer/filing/0001558370-24-012137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024012137/0001558370-24-012137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024012137/nrbo-20240814x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:20:48.824613+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}